The present studies were designed to determine the action of neutral endopeptidase inhibition (NEP-I), an inhibitor of the degradation of atrial natriuretic factor (ANF), in congestive heart failure (CHF). Studies were conducted in two groups of anesthetized dogs with CHF induced by 8 days of rapid right ventricular pacing. Group 1 (n=5) received a specific NEP-I (SQ 28,603) at two doses administered sequentially-30 mg/kg followed by a 60 mg/kg i.v. bolus. Group 2 (n=5) received intravenous infusion of exogenous ANF (100 ng/kg/min) to achieve increases in plasma ANF concentration as observed in group 1. NEP-I resulted in a diuresis and natriuresis (p<O.05) with increases in the fractional excretion of sodium and fractional excretion of lithium, the latter a marker for proximal tubule sodium delivery. Such tubular actions occurred in the absence of increases in glomerular filtration rate or renal blood flow but were associated with significant increases in urinary ANF and urinary cyclic GMP. Plasma ANF increased after the 30 mg/kg NEP-I dose. In contrast, in group 2 with exogenous ANF and despite a marked increase in plasma ANF, no natriuresis was observed. Arterial pressure did not change in either group. These studies demonstrate for the first time in CHF that NEP-I may potentiate the natriuretic action of endogenous ANF by a mechanism that is independent of systemic or renal hemodynamics and does not parallel increases in plasma ANF. These studies support an important therapeutic role for NEP-I in CHF. (Circulation 1990;82:196-201 
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Based on the markedly high concentration of NEP within the brush border vesicles of proximal tubules of the kidney, the present study tested the hypothesis that NEP-I in CHF may mediate a natriuretic action by renal tubular mechanism that is not dependent on increases in renal hemodynamics or parallel changes in circulating ANF. The present study was therefore designed to determine the cardiorenal response to a specific NEP-I (SQ 28,603) in experimental CHF in the dog induced by rapid ventricular pacing.
Methods
Experiments were performed in two groups of mongrel dogs weighing 16-24 kg with experimental CHF induced by 8 days of rapid right ventricular pacing. This model is characterized by changes in cardiac hemodynamics, circulating hormone adjustments, and marked sodium retention as observed in humans with chronic CHF. These animal studies conformed to the guiding principles of the American Physiological Society.
Two weeks before the acute experiment, programmable pacemakers (Medtronic 5320, Minneapolis, Minnesota) were implanted under pentobarbital anesthesia (30 mg/kg i.v.). The heart was exposed through a left thoracotomy incision at the fourth intercostal space. The pericardium was opened, and a screw-in epicardial pacemaker lead was implanted into the right ventricular myocardium. The pacemaker lead was then connected to the pacemaker generator, which was implanted subcutaneously within the chest. A chest tube was placed in the left thorax for drainage, and the thoracotomy incision closed. The chest tube was removed after adequate drainage. The dogs were then allowed to recover. Three to 5 days after implantation, the pacemaker was programmed at 250 beats/min. Dogs were then paced for 8 days, which resulted in the clinical signs of CHF. 17, 18 The dogs were fasted overnight before the acute experiment and given an oral dose of lithium (300 mg). Before the acute experiment, the dogs were anesthetized with fentanyl (0.005-0.01 mg/kg) and sodium pentobarbital (5-10 mg/kg) given intravenously. The anesthetics were slowly titrated with supplemental doses given as needed. The dogs were then intubated and artificially ventilated (Harvard Respirator, Harvard Apparatus, Millis, Massachusetts) with supplemental oxygen at 4 1/min.
The right external jugular vein was exposed and a flow-directed balloon-tipped thermodilution catheter (model 93-121A, 7F, American Edwards Laboratories, Santa Ana, California) was advanced into the pulmonary artery. Right atrial pressure was measured from the atrial port of the Swan-Ganz catheter. Both femoral veins were cannulated with polyethylene catheters for intravenous infusions of inulin and ANF or NEP-I. The right femoral artery was cannulated for measurement of arterial pressure and sampling of arterial blood.
A flank incision was made, and the left kidney was exposed. The ureter was cannulated for timed urine collections. An electromagnetic flow probe was placed on the left renal artery and connected to a flowmeter (model FM 5010, Carolina Medical Electronics, King, North Carolina). Blood flows and arterial pressure were recorded on a Gould Model 2200 strip recorder (Gould Electronics, Minneapolis, Minnesota).
Experimental Protocol
After completion of the surgical preparations, inulin and normal saline infusions at 1 ml/min were initiated. The amount of inulin infused was calculated to achieve a plasma concentration of 50 mg/dl. The dogs were allowed to stabilize for 60 minutes without intervention. At the end of the equilibration period, two consecutive 15-minute baseline clearances were obtained. The remainder of the protocol differed among the two groups. In group 1 (n=5) after the two baseline clearances, a 30 mg/kg i.v. bolus of a specific NEP-I (SQ 28,603, Squibb Institute for Medical Research, Princeton, New Jersey), with a structure similar to that recently reported by Delaney et al,19 was given over 5 minutes, and a 15-minute lead-in period was observed. Three 15-minute clearances were then obtained after which NEP-I 60 mg/kg by i.v. bolus was administered. Three 15-minute experimental clearances were then obtained. In group 2 (n=5), after two baseline 15-minute clearances, ANF (a-hANF, Peninsula, Belmont, California) was infused intravenously at 100 ng/kg/min, a dose estimated to achieve similar peak plasma concentrations for ANF as observed during NEP-I administration. After a 15-minute lead in infusion, three experimental 15-minute clearances were obtained.
Each clearance period consisted of a 15-minute urine collection, measurement of hemodynamic parameters, and withdrawal of 20 ml of arterial blood for hormonal analysis and electrolyte determination. Extracted arterial plasma levels of ANF and urinary ANF levels were measured by radioimmunoassay to a-hANF as previously described.20 Urine for cyclic GMP (cGMP) levels was collected on ice, and cGMP was measured by radioimmunoassay using the method of Steiner et al. 21 The hemodynamic data collected included mean arterial pressure (MAP), right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP) (to assess left atrial pressure), cardiac output (CO), and renal blood flow (RBF). CO was measured by ther- The present study reports for the first time the renal and cardiovascular actions of NEP-I in experimental CHF. In CHF with elevated endogenous ANF, NEP-I produced a significant natriuresis and diuresis that was not dependent on increases in GFR or RBF and did not parallel the increases in plasma ANF. Further, administration of exogenous ANF in a separate CHF group to mimic plasma levels achieved with NEP-I failed to enhance sodium and water excretion. Arterial pressure did not change with either NEP-I or exogenous ANF. Thus, these studies support a renal tubular action for NEP-I in CHF.
The current studies importantly extend previous published studies of the in vivo action of NEP-I. 25, 26 In studies by Koepke et al,25 NEP-I with thiorphan in the normal rat did not result in changes in plasma ANF, sodium excretion, or arterial pressure. Only in the presence of coadministration of a blocker of the ANF clearance receptor with an increase in plasma ANF was NEP-I associated with an increase in sodium excretion. No decrease in arterial pressure was observed. No assessment of renal hemodynamic or tubular function was performed. In preliminary studies by Samuels et al,13 NEP-I also was natriuretic only in the presence of increased plasma ANF produced by volume expansion. The present studies now demonstrate that NEP-I in CHF with chronically increased endogenous circulating ANF is natriuretic.
The most significant action of NEP-I in the present study in experimental CHF was to increase sodium excretion in the absence of changes in renal hemodynamics, although small but significant immeasurable changes cannot be excluded. Nevertheless, neither GFR nor RBF increased in response to NEP-I.
Thus, the mechanism of the increase in urinary sodium excretion, not investigated in previous investigations, is via inhibition of tubular reabsorption of sodium.
The renal tubular mechanism(s) of action of NEP-I remain unclear but is suggested by the localization of markedly high concentrations of NEP9,10 within proximal tubule brush border vesicles of the kidney. Studies Garvin.31 The current study also importantly extends our understanding of the renal hyporesponsiveness to elevated concentrations of endogenous ANF in CHF. Previous studies have suggested that the attenuated natriuretic response to elevated plasma ANF in CHF may be related to ANF receptor down-regulation32 and the opposing actions of counter-regulatory systems such as renal nerves33 and the intrarenal reninangiotensin system27 as well as decreased renal perfusion pressure. 34 The increase in sodium excretion in the present study in response to NEP-I, not observed with exogenous ANF, suggests that enhanced renal degradation of endogenous ANF in CHF may also contribute to the attenuated renal natriuretic response in CHF.
NEP-I increased circulating concentrations of ANF in our model of experimental CHF. Thus, inhibition of NEP may also serve as an important physiological and therapeutic tool to increase plasma ANF independent of exogenous peptide infusions. While a limited cardiorenal response to exogenous ANF was observed in the present study as compared with the renal action of NEP-1, more long-term administration of NEP-I to chronically elevate ANF in CHF may result in more long-term alterations in cardiorenal function as has been documented with chronic infusions of exogenous ANF in both animals and humans. 35, 36 In the present study, NEP-I did not decrease arterial pressure-nor did arterial pressure decrease with exogenous ANF infusion. This attenuated vasoactive action on arterial pressure has been previously documented in both animals and humans with CHF.8, 37 Thus, NEP-I in CHF has a selective renal action independent of changes in arterial pressure.
In conclusion, the present study demonstrates that NEP-I in CHF acts to decrease tubular reabsorption of sodium in this sodium-retaining state. Such an action may be secondary to inhibition of the renal degradation of endogenous ANF. This action appears independent of changes in systemic or renal hemodynamics and did not parallel changes in plasma ANF. Thus, NEP-I may serve as a novel therapeutic tool to enhance the renal natriuretic action of elevated endogenous ANF in CHF.
